What is the address of TM Pharma?

The registered office of TM Pharma is located at Leopold III-lei 13, 2650 Edegem.

Is TM Pharma still active?

Yes. According to the CBE (30 October 2026) TM Pharma is active, legal situation “Normale toestand”, started on 5 May 2006.

Is TM Pharma registered on Peppol?

Yes, TM Pharma is registered on the Peppol network with ID 0208:0881130182.

What is the enterprise number of TM Pharma?

The enterprise number of TM Pharma is BE0881130182.

When was TM Pharma founded?

TM Pharma was founded on 5 May 2006.

Who are the directors of TM Pharma?

According to the 2025 annual accounts, the directors of TM Pharma are: Tom Claes, Mieke Raemdonck.

Is TM Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 May 2006; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did TM Pharma make in 2025?

TM Pharma recorded a loss after taxes of € 45,372 in financial year 2025.

What is the revenue of TM Pharma?

As a small company, TM Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 49,149.

TM Pharma (Private Limited) - Edegem - BE0881130182

Q: What does TM Pharma do?

TM Pharma is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 5 May 2006, 1 establishment.

Dossier TM Pharma, printed on 30 October 2026 from databakkes.be/en/0881130182/tm-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

TM Pharma from Edegem, company number BE0881130182, closed financial year 2025 with a result of € -45,372 after tax. For that financial year TM Pharma recorded a gross margin of € 49,149 and equity of € 916,345. Compared with financial year 2024, the result moved from € 11,985 to € -45,372. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Healthy

€ 916,345

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -45,372

▼ still € 11,985 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 117,609

▲ € 101,697 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 897,745.

People and assets in 2025

Vehicles and equipment

€ 32,662

▲ 50% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 13 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 721,068

▲ 57% vs 2024

€ 55,142 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.

Owed to suppliers

€ 30,113

▲ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 15,069

▼ 3% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 134,213 Gross margin 2022: € 134,213 First fiscal year in the series	€ 95,747 Gross margin 2023: € 95,747 ▼ 29% vs 2022 (€ 134,213) Unfavourable step	€ 83,775 Gross margin 2024: € 83,775 ▼ 13% vs 2023 (€ 95,747) Unfavourable step	€ 49,149 Gross margin 2025: € 49,149 ▼ 41% vs 2024 (€ 83,775) Unfavourable step	▼ 41%
Profit after taxes	€ 95,791 Profit after taxes 2022: € 95,791 First fiscal year in the series	€ 27,779 Profit after taxes 2023: € 27,779 ▼ 71% vs 2022 (€ 95,791) Unfavourable step	€ 11,985 Profit after taxes 2024: € 11,985 ▼ 57% vs 2023 (€ 27,779) Unfavourable step	€ -45,372 Profit after taxes 2025: € -45,372 ▼ € 57,357 vs 2024 (€ 11,985) Unfavourable step	▼ € 57,357
Equity	€ 921,954 Equity 2022: € 921,954 First fiscal year in the series	€ 949,733 Equity 2023: € 949,733 ▲ 3% vs 2022 (€ 921,954) Favourable step	€ 961,718 Equity 2024: € 961,718 ▲ 1% vs 2023 (€ 949,733) Favourable step	€ 916,345 Equity 2025: € 916,345 ▼ 5% vs 2024 (€ 961,718) Unfavourable step	▼ 5%
Total debts	€ 708,298 Total debts 2022: € 708,298 First fiscal year in the series	€ 399,549 Total debts 2023: € 399,549 ▼ 44% vs 2022 (€ 708,298) Favourable step	€ 502,236 Total debts 2024: € 502,236 ▲ 26% vs 2023 (€ 399,549) Unfavourable step	€ 766,250 Total debts 2025: € 766,250 ▲ 53% vs 2024 (€ 502,236) Unfavourable step	▲ 53%
Cash	€ 64,674 Cash 2022: € 64,674 First fiscal year in the series	€ 9,307 Cash 2023: € 9,307 ▼ 86% vs 2022 (€ 64,674) Unfavourable step	€ 15,912 Cash 2024: € 15,912 ▲ 71% vs 2023 (€ 9,307) Favourable step	€ 117,609 Cash 2025: € 117,609 ▲ € 101,697 vs 2024 (€ 15,912) Favourable step	▲ € 101,697
Land & buildings	€ 777,702 Land & buildings 2022: € 777,702 First fiscal year in the series	€ 732,077 Land & buildings 2023: € 732,077 ▼ 6% vs 2022 (€ 777,702) Unchanged	€ 694,897 Land & buildings 2024: € 694,897 ▼ 5% vs 2023 (€ 732,077) Unchanged	€ 1,097,896 Land & buildings 2025: € 1,097,896 ▲ 58% vs 2024 (€ 694,897) Unchanged	▲ 58%
Retained profit	€ 903,354 Retained profit 2022: € 903,354 First fiscal year in the series	€ 931,133 Retained profit 2023: € 931,133 ▲ 3% vs 2022 (€ 903,354) Favourable step	€ 943,118 Retained profit 2024: € 943,118 ▲ 1% vs 2023 (€ 931,133) Favourable step	€ 897,745 Retained profit 2025: € 897,745 ▼ 5% vs 2024 (€ 943,118) Unfavourable step	▼ 5%
Dividend	€ 300,000 Dividend 2022: € 300,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 300,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 397,919 Bank debt 2022: € 397,919 First fiscal year in the series	€ 357,731 Bank debt 2023: € 357,731 ▼ 10% vs 2022 (€ 397,919) Favourable step	€ 460,516 Bank debt 2024: € 460,516 ▲ 29% vs 2023 (€ 357,731) Unfavourable step	€ 721,068 Bank debt 2025: € 721,068 ▲ 57% vs 2024 (€ 460,516) Unfavourable step	▲ 57%
Balance sheet total	€ 1,630,252 Balance sheet total 2022: € 1,630,252 First fiscal year in the series	€ 1,349,282 Balance sheet total 2023: € 1,349,282 ▼ 17% vs 2022 (€ 1,630,252) Unchanged	€ 1,463,953 Balance sheet total 2024: € 1,463,953 ▲ 8% vs 2023 (€ 1,349,282) Unchanged	€ 1,682,595 Balance sheet total 2025: € 1,682,595 ▲ 15% vs 2024 (€ 1,463,953) Unchanged	▲ 15%

Key figures of TM Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to TM Pharma?

What happened at TM Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 29, 2026 New annual accounts for financial year 2025: loss of € 45,372 (▼ € 57,357 vs 2024). Source: NBB ↗
May 12, 2006 New establishment in Edegem. KBO
May 5, 2006 Start of the company according to the CBE. KBO
2006 Tom Claes became a director. NBB
2006 Mieke Raemdonck became a director. NBB

In short

From € 95,791 profit in 2022 to € 45,372 loss in 2025.

Paid € 15,568 in corporate taxes since 2022.

Best year ever: 2022, with € 95,791 profit.

Paid out € 300,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Tom Claes

Mieke Raemdonck

TM Pharma

24 Apotheek 50%

CAM Immo 50%

Behind TM Pharma are Tom Claes and Mieke Raemdonck. It owns 50% of 24 Apotheek and 50% of CAM Immo itself.

Directors

According to the 2025 annual accounts

Tom Claes

Director

since 2006

Mieke Raemdonck

Director

Also active at: CITY-PHARMA

since 2006

Establishments

Establishment units

Physical locations of this company

Registered office

Leopold III-lei 13

2650 Edegem

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

CAM Immo same network

€ 86,267 gross margin · 2025

PROJECT AARTSELAAR

STAB Immo

€ 66,650 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0881.130.182

VAT number

BE 0881.130.182

Registered office

Leopold III-lei 13, 2650 Edegem

Names & denominations

TM Pharma · T&M Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 May 2006

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗